Blood cell counts during treatment of neuroendocrine tumors with [111-In-DTPA]octreotide

被引：0
|
作者：
van Hagen, PM
Valkema, R
Tse, WK
Kwekkeboom, DJ
de Herder, WW
Hooykaas, H
Krenning, EP
机构：
[1] Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands
[2] Erasmus Univ, Dept Nucl Med, NL-3000 DR Rotterdam, Netherlands
[3] Erasmus Univ, Dept Internal Med 3, NL-3000 DR Rotterdam, Netherlands
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1999年 / 26卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
PS620
引用
收藏
页码：1207 / 1207
页数：1
相关论文
共 50 条
  • [21] 111In-octreotide bone metastases detection in carcinoid tumors and pancreatic neuroendocrine tumors
    Banzo, J
    Abós, MD
    Prats, E
    Razola, P
    García, S
    Gomollón, F
    García, F
    Freile, E
    Escalera, T
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 1177 - 1177
  • [22] Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors?
    Kjell Öberg
    Endocrine, 2012, 42 : 3 - 4
  • [23] Gallium-68 somatostatin receptor PET/CT: Is it time to replace 111Indium DTPA octreotide for patients with neuroendocrine tumors?
    Oberg, Kjell
    ENDOCRINE, 2012, 42 (01) : 3 - 4
  • [24] The Role of 68Ga-DOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy
    Srirajaskanthan, Rajaventhan
    Kayani, Irfan
    Quigley, Anne Marie
    Soh, Jade
    Caplin, Martyn E.
    Bomanji, Jamshed
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (06) : 875 - 882
  • [25] Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours
    Castaldi, P.
    Rufini, V.
    Treglia, G.
    Bruno, I.
    Perotti, G.
    Stifano, G.
    Barbaro, B.
    Giordano, A.
    RADIOLOGIA MEDICA, 2008, 113 (07): : 1056 - 1067
  • [26] Treatment of gastroenteropancreatic neuroendocrine tumors with octreotide LAR.
    Tomassetti, P
    Migliori, M
    Lalli, S
    Corinaldesi, R
    Gullo, L
    GASTROENTEROLOGY, 2000, 118 (04) : A526 - A526
  • [27] Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors
    Woltering, EA
    Mamikunian, PM
    Zietz, S
    Krutzik, SR
    Go, VLW
    Vinik, AI
    Vinik, E
    O'Dorisio, TM
    Mamikunian, G
    PANCREAS, 2005, 31 (04) : 392 - 400
  • [28] The value of hybrid In-111-Octreotide SPECT/CT imaging in neuroendocrine tumors
    Vlachou, F.
    Pipikos, T.
    Vogiatzis, M.
    Dalianis, K.
    Nikaki, A.
    Papoutsani, D.
    Prassopoulos, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S472 - S472
  • [29] Radiation safety during treatment of neuroendocrine tumours with high dose Indium-111 octreotide
    Boot, CN
    Stokkel, MPM
    Blokland, JAK
    Pauwels, EKJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 1048 - 1048
  • [30] A comparison of biodistribution between 111In-DTPA octreotide and 111In-DOTATOC in rats bearing pancreatic tumors
    Lin, YC
    Hung, GU
    Luo, TY
    Chen, CH
    Hsia, CC
    Chen, SL
    Ho, YJ
    Lin, WY
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2006, 68 (04): : 367 - 371
12345